Why Moderna Stock Was Unhealthy This Week

422
28
Favorite

Why Moderna Stock Was Unhealthy This Week

Motley Fool2022-04-10

What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

422

Report

Comment（28）

Jawslea
·2022-04-11
Ok
Reply
1
Report
tinyseeker97
·2022-04-11
Lol
Reply
2
Report
SherryVJ
·2022-04-11
Ok
Reply
3
Report
Vincent1968
·2022-04-11
Ok
Reply
1
Report
Bull1973
·2022-04-11
Ok
Reply
2
Report
Xue91
·2022-04-11
Eth
Reply
3
Report
Xue91
·2022-04-11
Goh
Reply
1
Report
koolgal
·2022-04-11
Just a temporary setback for Moderna and hopefully things will get better for investors. 🙏🙏🙏
Reply
12
Report
JY_02222
·2022-04-10
Nice
Reply
5
Report
Chonky
·2022-04-10
Like please
Reply
6
Report
Kave
·2022-04-10
[Happy] [Happy]
Reply
4
Report
simplyZuan
·2022-04-10
Lol u should have made enough in the past 2 years. This pandemic is reaching the end
Reply
5
Report
TriciaChang
·2022-04-10
T
Reply
4
Report
V K
·2022-04-10
Pls like tyvm[Happy]
Reply
5
Report
Watchman21
·2022-04-10
So the only way for moderna to go up again by spreading the new variant [LOL]
Reply
3
Report
ccwee
·2022-04-10
read
Reply
5
Report
EY12
·2022-04-10
Like
Reply
5
Report
Zel Lim
·2022-04-10
Nice
Reply
4
Report
WilliamFish
·2022-04-10
O
Reply
3
Report
Thomas9413
·2022-04-10
Great
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2226748573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-10 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2226748573","market":"us","top_or_hot":-1,"title":"Why Moderna Stock Was Unhealthy This Week","media":"Motley Fool","content":"<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","article_id":"2226748573","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","pubTimestamp":1649558943,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The high-profile biotech gets slammed with a few pieces of bad news.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"为什么莫德纳股票本周不健康","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9014618737,"gmtCreate":1649648504436,"gmtModify":1676534544464,"author":{"id":"3581673258710248","authorId":"3581673258710248","name":"Jawslea","avatar":"https://static.tigerbbs.com/8333191726f8892d8ed5ce88d0ca4b94","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3581673258710248","authorIdStr":"3581673258710248"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014618737","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014632271,"gmtCreate":1649647403047,"gmtModify":1676534544272,"author":{"id":"4087606124924910","authorId":"4087606124924910","name":"tinyseeker97","avatar":"https://static.tigerbbs.com/16c3bc84b5291d6748e6ca8ba11acd19","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087606124924910","authorIdStr":"4087606124924910"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014632271","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014134029,"gmtCreate":1649632131590,"gmtModify":1676534539106,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://community-static.tradeup.com/news/1881722e980e541f3c66ed217d5b91c6","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"3586426326873853","authorIdStr":"3586426326873853"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014134029","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014106160,"gmtCreate":1649630181226,"gmtModify":1676534538401,"author":{"id":"3586393315819735","authorId":"3586393315819735","name":"Vincent1968","avatar":"https://community-static.tradeup.com/news/7f106edb1e06baf3c68462c050422f46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586393315819735","authorIdStr":"3586393315819735"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014106160","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014376308,"gmtCreate":1649628919621,"gmtModify":1676534538183,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584680402793671","authorIdStr":"3584680402793671"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014376308","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014348441,"gmtCreate":1649627454251,"gmtModify":1676534537833,"author":{"id":"3582021616632458","authorId":"3582021616632458","name":"Xue91","avatar":"https://static.tigerbbs.com/4d9f9012cc2ef597a6ee7470e2cfb3e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582021616632458","authorIdStr":"3582021616632458"},"htmlText":"Eth","listText":"Eth","text":"Eth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014348441","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014348540,"gmtCreate":1649627448137,"gmtModify":1676534537818,"author":{"id":"3582021616632458","authorId":"3582021616632458","name":"Xue91","avatar":"https://static.tigerbbs.com/4d9f9012cc2ef597a6ee7470e2cfb3e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582021616632458","authorIdStr":"3582021616632458"},"htmlText":"Goh","listText":"Goh","text":"Goh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014348540","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014355830,"gmtCreate":1649625717157,"gmtModify":1676534537659,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Just a temporary setback for Moderna and hopefully things will get better for investors. 🙏🙏🙏","listText":"Just a temporary setback for Moderna and hopefully things will get better for investors. 🙏🙏🙏","text":"Just a temporary setback for Moderna and hopefully things will get better for investors. 🙏🙏🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014355830","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014387275,"gmtCreate":1649605641136,"gmtModify":1676534536915,"author":{"id":"3581989267840978","authorId":"3581989267840978","name":"JY_02222","avatar":"https://static.tigerbbs.com/56c9cab1743301942105239814a6ac4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581989267840978","authorIdStr":"3581989267840978"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014387275","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014395636,"gmtCreate":1649601164779,"gmtModify":1676534536208,"author":{"id":"3581920930646755","authorId":"3581920930646755","name":"Chonky","avatar":"https://static.tigerbbs.com/2b26c78fb11a9e646bce483ea1b0d6f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581920930646755","authorIdStr":"3581920930646755"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014395636","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014398350,"gmtCreate":1649600327438,"gmtModify":1676534536126,"author":{"id":"4090112981805970","authorId":"4090112981805970","name":"Kave","avatar":"https://static.tigerbbs.com/7928a22910f1e6651ac7f9dbf8e9c369","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090112981805970","authorIdStr":"4090112981805970"},"htmlText":"[Happy]&nbsp;[Happy]&nbsp;","listText":"[Happy]&nbsp;[Happy]&nbsp;","text":"[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014398350","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014975459,"gmtCreate":1649597913905,"gmtModify":1676534535763,"author":{"id":"4099287919764600","authorId":"4099287919764600","name":"simplyZuan","avatar":"https://community-static.tradeup.com/news/dc20e2abf14d7b9fc985eba8704182f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4099287919764600","authorIdStr":"4099287919764600"},"htmlText":"Lol u should have made enough in the past 2 years.&nbsp; This pandemic is reaching&nbsp;the end","listText":"Lol u should have made enough in the past 2 years.&nbsp; This pandemic is reaching&nbsp;the end","text":"Lol u should have made enough in the past 2 years. This pandemic is reaching the end","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014975459","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014964393,"gmtCreate":1649587422547,"gmtModify":1676534534609,"author":{"id":"3560421500323385","authorId":"3560421500323385","name":"TriciaChang","avatar":"https://static.tigerbbs.com/5cb6619edb253a8bb8b2776c7d9b0e02","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3560421500323385","authorIdStr":"3560421500323385"},"htmlText":"T","listText":"T","text":"T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014964393","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014982203,"gmtCreate":1649584975049,"gmtModify":1676534534330,"author":{"id":"3577323914202336","authorId":"3577323914202336","name":"V K","avatar":"https://static.tigerbbs.com/536d624e5750dcffec704eeed9bc003b","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":8,"crmLevelSwitch":1,"idStr":"3577323914202336","authorIdStr":"3577323914202336"},"htmlText":"Pls like tyvm[Happy]&nbsp;","listText":"Pls like tyvm[Happy]&nbsp;","text":"Pls like tyvm[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014982203","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014983759,"gmtCreate":1649584452382,"gmtModify":1676534534167,"author":{"id":"3582355870744811","authorId":"3582355870744811","name":"Watchman21","avatar":"https://static.tigerbbs.com/0c680ac1c4e55428cfa53d9aa6ae6249","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582355870744811","authorIdStr":"3582355870744811"},"htmlText":"So the only way for moderna to go up again by spreading the new variant&nbsp;[LOL]&nbsp;","listText":"So the only way for moderna to go up again by spreading the new variant&nbsp;[LOL]&nbsp;","text":"So the only way for moderna to go up again by spreading the new variant [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014983759","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014074409,"gmtCreate":1649574463722,"gmtModify":1676534533118,"author":{"id":"3581829959470650","authorId":"3581829959470650","name":"ccwee","avatar":"https://static.tigerbbs.com/652d99331e3c23c682d7e58cfc9f6544","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581829959470650","authorIdStr":"3581829959470650"},"htmlText":"read","listText":"read","text":"read","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014074409","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014078950,"gmtCreate":1649573520820,"gmtModify":1676534533008,"author":{"id":"3569935580474431","authorId":"3569935580474431","name":"EY12","avatar":"https://static.tigerbbs.com/103e86782b34598ff73873d5f9259adb","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3569935580474431","authorIdStr":"3569935580474431"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014078950","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014050830,"gmtCreate":1649568614935,"gmtModify":1676534532313,"author":{"id":"4099285447763740","authorId":"4099285447763740","name":"Zel Lim","avatar":"https://static.tigerbbs.com/b101cc50a7f423e0f2a0e1f50035a3d2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4099285447763740","authorIdStr":"4099285447763740"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014050830","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014066701,"gmtCreate":1649566082653,"gmtModify":1676534531926,"author":{"id":"3584440700668924","authorId":"3584440700668924","name":"WilliamFish","avatar":"https://static.itradeup.com/news/78ded0486115bfde72a2c4335fa410ff","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584440700668924","authorIdStr":"3584440700668924"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014066701","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9014066898,"gmtCreate":1649566027049,"gmtModify":1676534531917,"author":{"id":"3585385605908328","authorId":"3585385605908328","name":"Thomas9413","avatar":"https://static.tigerbbs.com/effcfaa82ddb11a4fa57136b2a6f8351","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":1,"crmLevelSwitch":0,"idStr":"3585385605908328","authorIdStr":"3585385605908328"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9014066898","repostId":2226748573,"repostType":4,"repost":{"id":"2226748573","pubTimestamp":1649558943,"share":"https://ttm.financial/m/news/2226748573?lang=&edition=fundamental","pubTime":"2022-04-10 10:49","market":"us","language":"en","title":"Why Moderna Stock Was Unhealthy This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2226748573","media":"Motley Fool","summary":"The high-profile biotech gets slammed with a few pieces of bad news.","content":"<html><head></head><body><h2>What happened</h2><p>The very model of a coronavirus stock in many eyes, <b>Moderna</b>&#39;s price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we&#39;ve witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech&#39;s stock down by almost 9% in the Monday-to-Friday stretch.</p><h2>So what</h2><p>The week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only two COVID jabs the regulator has fully approved for use.</p><p>But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization&#39;s (WHO) COVAX vaccine initiative. That entity said &#34;no&#34; to a combined 166 million doses for 2022&#39;s third and fourth quarters.</p><p>Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.</p><h2>Now what</h2><p>I don&#39;t think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Was Unhealthy This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Was Unhealthy This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-10 10:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2022/04/08/why-moderna-stock-was-unhealthy-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2226748573","content_text":"What happenedThe very model of a coronavirus stock in many eyes, Moderna's price has generally been on the decline recently. This broadly matches the falls in COVID-19 cases and fatalities we've witnessed in many jurisdictions throughout the world in recent weeks. But there were other factors at play during the week, and these drove the biotech's stock down by almost 9% in the Monday-to-Friday stretch.So whatThe week started out well for Moderna. On Monday, the U.S. Food and Drug Administration (FDA) announced that a team of expert advisors would meet to discuss the timing of, and patient eligibility for, additional coronavirus vaccine boosters. The biotech is the developer of mRNA-1273, also known as Spikevax, one of only two COVID jabs the regulator has fully approved for use.But on Wednesday, two large organizations declined to exercise their options for additional mRNA-1273 doses. The first was the 55-country African Union, which turned down a 60 million-dose delivery it was entitled to for the second quarter. The second was the World Health Organization's (WHO) COVAX vaccine initiative. That entity said \"no\" to a combined 166 million doses for 2022's third and fourth quarters.Compounding this negative development, on Friday Moderna said it was recalling 764,900 doses of the shot that were distributed in Europe and made by Rovi, its contract manufacturer. Moderna said a vial contaminated by a foreign body was found, and the recall was being undertaken as a precautionary measure.Now whatI don't think investors should be overly discouraged by the recent bad news. mRNA-1273 is still one of the best weapons in our anti-COVID arsenal, and we might have to arm up once again if the current omicron BA.2 variant becomes a real threat. Moderna bulls should probably stay the course with their stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":422,"commentSize":28,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}